Your browser doesn't support javascript.
loading
The future of protein scaffolds as affinity reagents for purification.
Dias, Ana M G C; Roque, Ana C A.
Afiliação
  • Dias AM; UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Campus Caparica, Caparica, 2829-516, Portugal.
  • Roque AC; UCIBIO, REQUIMTE, Departamento de Química, Faculdade de Ciências e Tecnologia, Universidade Nova de Lisboa, Campus Caparica, Caparica, 2829-516, Portugal.
Biotechnol Bioeng ; 114(3): 481-491, 2017 03.
Article em En | MEDLINE | ID: mdl-27568828
ABSTRACT
Affinity purification is one of the most powerful separation techniques extensively employed both at laboratory and production scales. While antibodies still represent the gold standard affinity reagents, others derived from non-immunoglobulin scaffolds emerged as interesting alternatives in particular for affinity purification. The lower costs of production, fast ligand development, and high robustness are appealing advantages of non-immunoglobulin scaffolds. These have successfully been used in the affinity purification of relevant targets as antibodies, human serum albumin, transferrin, and other biomarkers, as reviewed in this work. Furthermore, a critical assessment on the strengths, weaknesses, opportunities, and threats related with the implementation of non-immunoglobulin scaffolds as ligands in affinity purification are discussed. Biotechnol. Bioeng. 2017;114 481-491. © 2016 Wiley Periodicals, Inc.
Assuntos
Palavras-chave

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes / Engenharia de Proteínas / Cromatografia de Afinidade Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Proteínas Recombinantes / Engenharia de Proteínas / Cromatografia de Afinidade Limite: Animals / Humans Idioma: En Ano de publicação: 2017 Tipo de documento: Article